datma and Rhythm Biosciences Announce Collaboration to Apply Federated Real-World Data to Genomic Diagnostic Development
datma, a provider of federated real-world data access, and Rhythm Biosciences Ltd (ASX:RHY), a developer in predictive cancer diagnostics technology, have announced an exploratory collaboration. This initiative aims to evaluate how datma.FED, datma's…
datma, a provider of federated real-world data access, and Rhythm Biosciences Ltd (ASX:RHY), a developer in predictive cancer diagnostics technology, have announced an exploratory collaboration. This initiative aims to evaluate how datma.FED, datma's federated data platform, can support and accelerate the commercialization of Rhythm's genomic-integrated cancer risk prediction portfolio.
As genomic-integrated stratification tools advance, access to high-quality real-world data is crucial for development, model performance enhancement, and clinical relevance. Fragmentation and privacy constraints often limit the accessibility of these datasets. datma.FED addresses these challenges by enabling secure, federated access to de-identified data across participating healthcare organizations without centralizing or moving the data.
The collaboration between datma and Rhythm Biosciences will assess how longitudinal, de-identified real-world clinical data available through datma.FED can contribute to the development of Rhythm’s genomic-integrated risk scoring technologies. Rhythm plans to explore these datasets to support clinical utility evidence generation and health economic modeling, which are important for discussions with healthcare systems regarding the adoption of population-based risk stratification tools.
Noah Nasser, CEO at datma, stated, "datma.FED was built to enable secure access to high-value data across institutions, and this collaboration reflects the growing demand for federated access to data that can support development and research efforts."
Fragmentation and privacy constraints often limit the accessibility of these datasets.
Dr. Erika Spaeth, Director of Clinical Affairs at Rhythm Biosciences, noted, "Access to high-quality real-world data is increasingly important in demonstrating the clinical relevance and potential utility of genomic-integrated risk prediction tools."
Rhythm Biosciences Ltd (ASX: RHY) is an Australian medical diagnostics company focused on creating simple, affordable blood tests for early cancer detection. The company aims to improve patient outcomes through early detection, thereby reducing the global cancer burden. Founded in 2017 and headquartered in Melbourne, Australia, more information can be found at rhythmbio.com .
Headquartered in Beaverton, OR, datma is transforming healthcare data access through a secure, federated ecosystem. Its platform, datma.FED, supports compliant, privacy-preserving collaboration without requiring data movement. The platform maximizes data utility with minimal technical effort from participating organizations. More information is available at www.datma.com .
vikki@oakstreetcommunications.com Rhythm Biosciences Ltd.
Based on reporting by TechBullion.